First-in-human phase I study of pictilisib (GDC-0941), a potent pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor, in patients with advanced solid tumors.
- Submitting institution
-
Institute of Cancer Research: Royal Cancer Hospital (The)
- Unit of assessment
- 1 - Clinical Medicine
- Output identifier
- 88
- Type
- D - Journal article
- DOI
-
10.1158/1078-0432.CCR-14-0947
- Title of journal
- Clin Cancer Res
- Article number
- -
- First page
- 77
- Volume
- 21
- Issue
- 1
- ISSN
- 1557-3265
- Open access status
- Out of scope for open access requirements
- Month of publication
- November
- Year of publication
- 2014
- URL
-
-
- Supplementary information
-
https://clincancerres.aacrjournals.org/content/21/1/77.figures-only
- Request cross-referral to
- -
- Output has been delayed by COVID-19
- No
- COVID-19 affected output statement
- -
- Forensic science
- No
- Criminology
- No
- Interdisciplinary
- Yes
- Number of additional authors
-
21
- Research group(s)
-
-
- Citation count
- 163
- Proposed double-weighted
- No
- Reserve for an output with double weighting
- No
- Additional information
- -
- Author contribution statement
- a) The author made a substantial contribution to the conception and design of the study; the organisation of the conduct of the study; analysis and interpretation of study data.
b) The author helped draft the output
- Non-English
- No
- English abstract
- -